30PD - Novel plasma circulating microRNA signature for early detection of non-small cell lung cancer in liquid biopsy

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Biomarkers
Topics Non-small-cell lung cancer
Aetiology, epidemiology, screening and prevention
Translational Research
Basic Scientific Principles
Basic Principles in the Management and Treatment (of cancer)
Presenter Tomasz Powrózek
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors T. Powrózek1, P. Krawczyk1, D. Kowalski2, B. Kuźnar-Kamińska3, K. Winiarczyk4, M. Olszyna-Serementa2, H. Batura-Gabryel3, J. Milanowski1
  • 1Pneumonology, Oncolgy And Allergology, Medical University of Lublin, 20-954 - Lublin/PL
  • 2Lung And Chest Tumors, Institute of Oncology, 02-034 - Warsaw/PL
  • 3Pulmunology, Allergology And Respiratory Oncology, Poznan University of Medical Sciences, 60-569 - Poznan/PL
  • 4Lung And Chest Tumors, MSC Memorial Cancer Centre and Institute Maria Sklodowska-Curie, 02-781 - Warsaw/PL

Abstract

Background

Significant difference in microRNAs (miRNAs) expression is frequently observedbetween cancer patients and healthy individuals. Moreover, possibility of miRNAs detection in blood samples (liquid biopsy) make them valuable biomarkers of early stage tumor development, including non-small cell lung cancer (NSCLC).

Methods

The aim of the study was evaluation of novel circulating miRNAs-448, 506, 944, 3662, 4316 and 4478 as biomarkers of early stage NSCLC development. miRNAs expression was analysed in plasma samples of 80 NSCLC patients (45 patients in stage I-IIIA and 35 patients in stage IIIB-IV) and 80 healthy individuals using qRT-PCR method. The diagnostic accuracy of studied biomarkers was assessed using logistic regression model and receiver operating curves (ROC) with area under curve (AUC) analysis.

Results

Significantly higher expression of miRNA-448, 944, 3662 and 4478 was detected in plasma of lung cancer patients compared with healthy individuals (p 

Conclusions

Novel signature of 4 circulating miRNAs may be considered as valuable diagnostic tool which could improve non-invasive diagnosis of NSCLC or complements CT lung screening. Moreover, miRNA-944 may be considered as marker of early differentiation of squamous cell carcinoma, whereas miRNA-3662 as early adenocarcinoma marker. The above findings confirms localization of gene encoding miRNA-944 within intron of p63 gene (its expression is marker of squamous differentiation). Whereas, miRNA-3662 sequence is complementary to mRNA of suppressor genes (PTAR1, SEPT10 and NPR3), which disorders are associated with adenocarcinoma differentiation.

Clinical trial identification

Legal entity responsible for the study

Approved by the local Ethical Committee of Medical University of Lublin (KE-0254/218/2015)

Funding

Medical University of Lublin

Disclosure

All authors have declared no conflicts of interest.